Xiaoke Pan
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.
Journal: Journal of the American Heart Association
Published: July 25, 2026
BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: January 21, 2026
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.
Journal: Critical care (London, England)
Published: December 08, 2023
Riociguat inhibits ultra-large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients.
Journal: Pulmonary circulation
Published: August 31, 2022
Epigenetic Modification of the von Willebrand Factor Promoter Drives Platelet Aggregation on the Pulmonary Endothelium in Chronic Thromboembolic Pulmonary Hypertension.
Journal: American journal of respiratory and critical care medicine
Published: January 26, 2022
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Journal: American journal of respiratory cell and molecular biology
Published: December 02, 2020
Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells.
Journal: Angiogenesis
Published: May 20, 2020
MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
Journal: International journal of molecular sciences
Published: April 21, 2020
Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Journal: The Journal of pathology
Published: November 25, 2018
Last Updated: 09/26/2026